A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to assess how well TAR-200 works in real-word by measuring the time taken from the first TAR-200 insertion to worsening of cancer or until the signs and symptoms of cancer occur again (disease-free survival) in participants with non-muscle invasive bladder cancer (NMIBC; an early-stage bladder cancer that is limited to the inner lining of bladder).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona diagnoza wczesnego raka pęcherza moczowego.
- •Pierwsza dawka leku TAR-200 podana w ciągu ostatnich 6 tygodni.
- •Pacjentki w wieku rozrodczym muszą stosować zalecane metody antykoncepcji.
- •Wyrażenie świadomej zgody na udział w badaniu.
✗ Disqualifies
- •Stan zdrowia uniemożliwiający przyjęcie leku TAR-200.
- •Wcześniejsze przerwanie leczenia TAR-200.
- •Otrzymanie leku TAR-200 w ramach innego badania klinicznego.
- •Przyjęcie więcej niż 2 dawek leku TAR-200 w normalnym leczeniu.
- •Udział w innym aktywnym badaniu dotyczącym raka pęcherza moczowego.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 6, 2026
- Sex
- No restrictions
Locations (13)
University of Alabama at Birmingham
Birmingham, United States
Arkansas Urology
Little Rock, United States
USC Norris Comprehensive Cancer Center
Los Angeles, United States
Cedars Sinai Medical Center
Los Angeles, United States
Colorado Clinical Research
Lakewood, United States
Florida Urology Partners
Wimauma, United States
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, United States
Specialty Clinical Research of St Louis
St Louis, United States
SUNY Upstate Med Univ
Syracuse, United States
Urology Specialists of the Carolinas PLLC Charlotte
Charlotte, United States
Urology Specialists of South Dakota
Sioux Falls, United States
UPNT Research Institute
Arlington, United States
Spokane Urology
Spokane, United States
Trial contact
Study Contact
Eliza M. Raymundo, MD, DMCC, FPUA, FPCS
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.